CN113403231B - Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof - Google Patents
Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof Download PDFInfo
- Publication number
- CN113403231B CN113403231B CN202110773458.0A CN202110773458A CN113403231B CN 113403231 B CN113403231 B CN 113403231B CN 202110773458 A CN202110773458 A CN 202110773458A CN 113403231 B CN113403231 B CN 113403231B
- Authority
- CN
- China
- Prior art keywords
- ccfm1178
- lactobacillus reuteri
- metabolic syndrome
- mice
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 109
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 108
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 63
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000000968 intestinal effect Effects 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 235000021107 fermented food Nutrition 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 210000005228 liver tissue Anatomy 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 42
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- 239000002158 endotoxin Substances 0.000 abstract description 24
- 210000002966 serum Anatomy 0.000 abstract description 20
- 210000004185 liver Anatomy 0.000 abstract description 17
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 15
- 235000009200 high fat diet Nutrition 0.000 abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 13
- 210000001072 colon Anatomy 0.000 abstract description 12
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 8
- 230000000770 proinflammatory effect Effects 0.000 abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000010469 Glycine max Nutrition 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 10
- 244000068988 Glycine max Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000007710 freezing Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 210000003486 adipose tissue brown Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 235000018823 dietary intake Nutrition 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 6
- 229960002327 chloral hydrate Drugs 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 229960003105 metformin Drugs 0.000 description 6
- 239000003223 protective agent Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 108090000600 Claudin-1 Proteins 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000012055 fruits and vegetables Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 244000174681 Michelia champaca Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- -1 fenofibrate Chemical class 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 235000015142 cultured sour cream Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses lactobacillus reuteri CCFM1178 capable of intervening in metabolic syndrome and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1178 screened by the method can obviously improve the serum total cholesterol content and the low-density lipoprotein cholesterol increase of a mouse with metabolic syndrome caused by high-fat diet, relieve the weight rise of an individual with the metabolic syndrome, and reduce daily diet intake and energy conversion efficiency; improving the imbalance of intestinal flora of mice caused by high fat; improving the level of proinflammatory factors IL-6 and TNF-alpha in the liver of a mouse with metabolic syndrome, improving the level of an anti-inflammatory factor IL-10 to prevent the metabolic syndrome, inhibiting serum lipopolysaccharide endotoxin and maintaining the colon barrier structure. The lactobacillus reuteri CCFM1178 can be used for preparing medicines or functional foods for relieving the diseases such as metabolic syndrome, non-alcoholic fatty liver, diabetes and the like, and has very wide application prospect.
Description
Technical Field
The invention relates to lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof, and belongs to the technical field of microorganisms.
Background
Metabolic Syndrome (MS) is a group of clinical syndromes that are characterized by the presence of central obesity, hyperglycemia (diabetes or impaired glucose regulation), dyslipidemia (including high TG and/or low HDL-C blood disease), hypertension, etc., and the accumulation of various risk factors based on pathological changes of glucose metabolism and lipid metabolism, and the promotion of development of various cardiovascular and cerebrovascular diseases such as type II diabetes and atherosclerosis. In recent years, with the continuous development of the economic and social level of China, the living standard of the public is continuously improved, the specific gravity of carbohydrates and grease in the dietary structure is increased day by day, and the people have a habit of sedentary sitting due to the limitation of various working conditions. The external environmental factors are combined with the genetic factors of the external environmental factors to greatly improve the prevalence rate of the metabolic syndrome of the population in China. It has been shown that about 7700 million patients with metabolic syndrome exist in the country, i.e. 1 in 8 adults have metabolic syndrome. The prevalence rate of metabolic syndrome of old people over 60 years old in China is 25%, and the prevalence rate is gradually increased with the age. Therefore, it is necessary to find a suitable means for alleviating metabolic syndrome.
The treatment measures adopted aiming at the metabolic syndrome at present mainly comprise strengthening exercise and improving diet and combining drug therapy, and the aims are all various risk factors for controlling and improving the metabolic syndrome, and mainly comprise weight-reducing drugs such as orlistat and lorcaserin; insulin resistance reducing agents such as metformin, thiazolidinediones (rosiglitazone, pioglitazone, etc.); fibrates that lower blood lipids such as fenofibrate, and statins that lower cholesterol such as simvastatin, etc.; angiotensin converting enzyme inhibitor for lowering blood pressure such as captopril. These drugs have good curative effects on single risk factors of metabolic syndrome, but have certain side effects after long-term administration, such as stimulation of gastrointestinal tract of some patients caused by long-term administration of metformin and possible influence on absorption of vitamin B12 by the patients, and rosiglitazone caused liver function damage and edema.
There are many studies reporting that the intestinal flora plays an extremely important role in the physiological metabolism of the human body, and the structural disorder of the intestinal flora is related to various diseases, including gastrointestinal diseases (irritable bowel syndrome, inflammatory bowel disease and the like), metabolic diseases (obesity, hyperlipidemia, diabetes and the like). The occurrence of metabolic syndrome is closely related to the imbalance of intestinal flora, and common intestinal flora regulating preparations comprise probiotics, prebiotics and the like. The probiotics is edible microorganisms beneficial to human health, and has the potential functions of relieving blood sugar and dyslipidemia, and regulating intestinal flora structure and brain and intestinal axis. For example, CN107699517A discloses a bifidobacterium adolescentis strain and application thereof, which can obviously improve pathological damage of liver and duodenum of a mouse with metabolic syndrome caused by high fat diet, and increase of triglyceride and total cholesterol content and oral glucose tolerance in serum; CN107523526A discloses a Lactobacillus reuteri and its use, which can reduce the serum lipid and blood sugar level of mice with metabolic syndrome; CN105567586A discloses a Lactobacillus plantarum NCU116 with an anti-diabetic function, which can achieve the anti-diabetic effect by regulating the blood sugar, blood fat and hormone levels of the organism and regulating the metabolic pathways in the organism. However, the above patents all use probiotics to relieve metabolic syndrome, and few studies are currently made on how probiotics inhibit endotoxin and protect colon intestinal barrier.
Disclosure of Invention
The invention aims to provide Lactobacillus reuteri (Lactobacillus reuteri) CCFM1178 which is preserved in Guangdong province microorganism strain preservation center at 19.03.2021, wherein the preservation number is GDMCC No.61574, and the preservation address is No. 5 th of Michelia Tokyo No. 100 college No. 59.
The lactobacillus reuteri CCFM1178 has the following biological characteristics:
(1) the characteristics of the thallus are as follows: the product is gram-positive, slender rod-shaped, has no flagellum and no spore;
(2) bacterial colony characteristics: culturing for 36 hours to form obvious convex colonies, wherein the edges are irregular, milky white and opaque, the surface is moist and smooth, and no pigment is generated;
(3) growth characteristics: culturing in MRS culture medium at 37 deg.C for about 18 hr to reach stationary phase;
(4) the medicinal safety is as follows: has no toxic and side effects on C57BL/6J mice.
The Lactobacillus reuteri (Lactobacillus reuteri) CCFM1178 can relieve metabolic syndrome, regulate intestinal flora and relieve irritable bowel syndrome, and is specifically embodied in that:
(1) reducing the body weight of individuals with metabolic syndrome, and improving high fat diet to cause excessive weight gain;
(2) reducing fasting blood glucose level of individuals with metabolic syndrome, and improving insulin resistance index of individuals with metabolic syndrome;
(3) reducing serum total cholesterol in individuals with high fat diet-induced metabolic syndrome;
(4) restoring abnormal intestinal flora of individuals with metabolic syndrome caused by high fat;
(5) serum low density lipoprotein of individual with metabolic syndrome;
(6) reducing body fat and epididymis fat index of individual with metabolic syndrome;
(7) has positive effect on bacterial lipopolysaccharide endotoxin induced inflammation;
(8) helping to maintain the colon barrier structure.
The second purpose of the invention is to provide the application of the lactobacillus reuteri CCFM1178 in preparing medicines.
In one embodiment, the medicament has at least one of the following functions:
(a) relieving metabolic syndrome;
(b) regulating intestinal flora;
(c) relieving irritable bowel syndrome;
(d) relieving inflammation and fibrosis of liver tissue.
In one embodiment, the symptoms exhibited by the metabolic syndrome include hyperglycemia, hyperlipidemia, and/or hepatic oxidative stress.
In one embodiment, the content of the Lactobacillus reuteri CCFM1178 in the medicament is more than or equal to 1 x 10 8 CFU/g or 1X 10 8 CFU/mL。
In one embodiment, the medicament further comprises a pharmaceutically acceptable excipient.
In one embodiment, the pharmaceutically acceptable excipients include one or more of fillers, binders, wetting agents, disintegrants, lubricants, flavoring agents.
In one embodiment, the dosage form of the medicament is granules, capsules, tablets, pills or oral liquid.
The third purpose of the invention is to provide a composition containing the lactobacillus reuteri CCFM 1178.
In one embodiment, the composition is a microbial preparation comprising wet cells or lyophilized cells of said lactobacillus reuteri CCFM 1178.
In one embodiment, the viable count of Lactobacillus reuteri CCFM1178 in the microbial preparation is greater than or equal to 1 × 10 6 CFU/g。
In one embodiment, the microbial preparation is prepared by: inoculating Lactobacillus reuteri CCFM1178 into MRS culture medium, culturing at 37 deg.C under anaerobic condition for 18-20 hr, collecting thallus, and resuspending thallus cells with protective agent to make the concentration of thallus reach 1 × 10 10 CFU/ml, culturing the suspension at 37 deg.C under anaerobic condition for 50-70min, and drying.
In one embodiment, the MRS medium contains per liter: 10g of tryptone, 10g of beef extract, 5g of yeast powder, 20g of glucose, 5g of sodium acetate, 2g of diammonium hydrogen citrate, 2g of dipotassium hydrogen phosphate, 0.5g of magnesium sulfate heptahydrate, 801ml of tween and 0.25g of manganese sulfate monohydrate.
In one embodiment, the protective agent comprises skimmed milk powder, maltodextrin, trehalose.
In one embodiment, the protectant comprises: 100g/L-150g/L skimmed milk powder, 100g/L-150g/L maltodextrin and 140g/L-160g/L trehalose.
In one embodiment, the collected bacterial cells are washed 2-4 times with a phosphate buffer having a pH of 6.8-7.2.
In one embodiment, the drying may be performed by any one of a number of methods including, but not limited to, vacuum freeze drying.
In one embodiment, the vacuum freeze-drying is performed after pre-freezing at-15 to-20 ℃ for 8 to 14 hours.
In one embodiment, the composition is a functional food or nutraceutical.
In one embodiment, the composition is a fermented food product produced by fermentation using lactobacillus reuteri CCFM1178, including solid food products, liquid food products, semi-solid food products.
In one embodiment, the fermented food product comprises a dairy product, a soy product, or a fruit and vegetable product; the dairy product comprises milk, sour cream or cheese; the raw materials of the fruit and vegetable product comprise cucumber, carrot, beet, celery or cabbage product.
The invention also claims the application of the lactobacillus reuteri CCFM1178 in preparing food or health care products.
The invention has the following beneficial effects and advantages:
the lactobacillus reuteri CCFM1178 has the effect of improving metabolic syndrome; specifically, the amelioration of metabolic syndrome includes: reducing the body weight of a subject with metabolic syndrome, reducing the fasting blood glucose level of a subject with metabolic syndrome, reducing the glucose tolerance of a subject with metabolic syndrome, reducing the serum total cholesterol of a mouse with high fat diet-induced metabolic syndrome, reducing the serum low density lipoprotein of a subject with metabolic syndrome, reducing the body fat of a subject with metabolic syndrome, and/or reducing the epididymal fat index of a subject with metabolic syndrome and increasing the brown fat index; restoring the imbalance of the intestinal flora of the mice caused by high fat; can restore the abnormal abundance of flora in the excrement of mice with the high fat diet induced metabolic syndrome, has positive effect on the induction of inflammation by bacterial lipopolysaccharide endotoxin, and has better effect on maintaining the colon barrier structure. The lactobacillus reuteri CCFM1178 can be used for preparing health-care food or medicine for relieving metabolic syndrome and regulating intestinal flora to relieve irritable bowel syndrome, and has very wide application prospect.
Biological material preservation
Lactobacillus reuteri (Lactobacillus reuteri) is classified and named as Lactobacillus reuteri, and is preserved in Guangdong province microorganism culture collection center in 2021, 3 and 19 days, and the preservation address is No. 59 building 5 of Michelia Tokyo No. 100, Michelia Tokyo, Guangzhou city, and the preservation number is GDMCC No. 61574.
Drawings
FIG. 1 shows the effect of Lactobacillus reuteri CCFM1178 on the intestinal flora of mice with metabolic syndrome;
FIG. 2 shows the effect of Lactobacillus reuteri CCFM1178 on the percent weight gain, epididymal fat index and brown fat index in mice with metabolic syndrome;
FIG. 3 shows the effect of Lactobacillus reuteri CCFM1178 on the daily dietary intake and energy conversion efficiency of the mice with metabolic syndrome;
FIG. 4 shows the effect of Lactobacillus reuteri CCFM1178 on serum Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in mice with metabolic syndrome;
FIG. 5 shows the effect of Lactobacillus reuteri CCFM1178 on the hepatic proinflammatory factors IL-6 and TNF- α in mice with metabolic syndrome;
FIG. 6 shows the effect of Lactobacillus reuteri CCFM1178 on the hepatic anti-inflammatory factor IL-10 in mice with metabolic syndrome;
FIG. 7 shows the effect of Lactobacillus reuteri CCFM1178 on serum Lipopolysaccharide (LPS) endotoxin in mice with metabolic syndrome;
FIG. 8 shows the effect of Lactobacillus reuteri CCFM1178 on the expression level of the zon-1, Occludin and Claudin-1 genes in colon tissue of the metabolic syndrome mouse;
(Note: p <0.05, p <0.01)
Detailed Description
The lactobacillus reuteri CCFM1178 has the following biological characteristics:
(1) the characteristics of the thallus are as follows: is gram-positive, slender rod-shaped, has no flagellum and no spore;
(2) colony characteristics: culturing for 36 hours to form obvious convex colonies, wherein the edges are irregular, milky white and opaque, the surface is moist and smooth, and no pigment is generated;
(3) growth characteristics: culturing in MRS culture medium at 37 deg.C for about 18 hr to reach stationary phase;
(4) the composition has no toxic or side effect on C57BL/6J mice;
(5) can remarkably improve the excessive weight gain caused by high fat diet;
(6) can remarkably regulate the inflammation level of the liver of a mouse with high fat diet;
(7) can remarkably recover the imbalance of the flora in the intestinal tract caused by high fat diet;
(8) reduce appetite and efficiency of dietary intake;
(9) can regulate the total cholesterol and low density lipoprotein cholesterol content in serum, and reduce the total cholesterol and low density lipoprotein cholesterol content to normal level;
(10) has positive effect on bacterial lipopolysaccharide endotoxin induced inflammation;
(11) maintaining the colon barrier structure has a good effect.
Example 1: screening and identification of Lactobacillus reuteri CCFM1178
Separation and screening of lactic acid bacteria
(1) 1g of pig manure from Lijiang City of Yunnan province is taken. After gradient dilution, the suspension was spread on a solid culture medium (each 1L of MRS medium contains 0.02g of vancomycin and 20g of agar, and the pH value was 5.0. + -. 0.1) for lactobacillus high selection, and cultured at 37 ℃ for 48 to 72 hours.
(2) Observing and recording colony morphology, picking colonies and streaking for purification.
(3) The colonies were gram-stained in MRS liquid medium at 37 ℃ for 24 hours, and the morphology of the colonies was recorded.
(4) Removing gram-negative bacteria strains and gram-positive cocci from the colonies, and selecting to obtain gram-positive bacilli.
(5) After catalase analysis, catalase-positive strains were discarded, and catalase-negative strains were retained.
Molecular biological identification of lactobacillus reuteri
(1) Extraction of genome of individual bacterium (performed according to the TIANAmp Bacteria DNA kit protocol)
A. Culturing the lactic acid bacteria obtained by screening in the step (II) overnight, taking 1mL of the bacterial suspension into a 1.5mL centrifuge tube, centrifuging for 1min at 10,000 rpm (11,500 Xg), and sucking the supernatant as far as possible;
B. to the pellet was added 180. mu.L of a buffer (20mM Tris, pH 8.0; 2mM Na) 2 -EDTA; 1.2% Triton; lysozyme with the final concentration of 20mg/mL (the lysozyme must be prepared by dissolving lysozyme dry powder in a buffer solution, otherwise, lysozyme can be inactivated), and the lysozyme is treated at 37 ℃ for more than 30 min;
C. adding 20 mu L of protease K solution into the tube, and uniformly mixing;
D. adding 220 μ L buffer solution GB, oscillating for 15sec, standing at 70 deg.C for 10min, cleaning the solution, and centrifuging briefly to remove water droplets on the inner wall of the tube cover;
E. adding 220 μ L anhydrous ethanol, mixing thoroughly for 15sec under shaking, wherein flocculent precipitate may appear, and centrifuging for a short time to remove water drop on the inner wall of the tube cover;
F. adding the solution and flocculent precipitate obtained in the previous step into an adsorption column CB3 (the adsorption column is placed into a collecting pipe), centrifuging at 12,000 rpm (-13,400 Xg) for 30sec, pouring the waste liquid, and placing an adsorption column CB3 into the collecting pipe;
G. adding 500 μ L buffer GD (checking whether absolute ethanol is added before use) into adsorption column CB3, centrifuging at 12,000 rpm (-13,400 Xg) for 30sec, pouring off waste liquid, and placing adsorption column CB3 into a collection tube;
H. adding 600 μ L of rinsing liquid PW (checking whether absolute ethanol is added before use) into adsorption column CB3, centrifuging at 12,000 rpm (-13,400 Xg) for 30sec, discarding the waste liquid, and placing adsorption column CB3 into the collection tube; repeating the operation once;
I. putting the adsorption column CB3 back into the collecting pipe, centrifuging at 12,000 rpm (13,400 Xg) for 2min, pouring off waste liquid, and placing the adsorption column CB3 at room temperature for a plurality of minutes to thoroughly dry the residual rinsing liquid in the adsorption material;
J. transferring the adsorption column CB3 into a clean centrifuge tube, suspending and dripping 50-200 mu L of elution buffer TE into the middle part of the adsorption membrane, standing for 2-5min at room temperature, centrifuging for 2min at 12,000 rpm (13,400 Xg), and collecting the solution into the centrifuge tube.
35 strains are obtained by co-screening, and the strain with the serial number of CCFM1178 is identified as Lactobacillus reuteri (Lactobacillus reuteri) through 16S rDNA amplification and sequence comparison.
Example 2: tolerance of lactobacillus reuteri CCFM1178 to simulated gastrointestinal fluids
Inoculating the frozen lactobacillus reuteri CCFM1178 into an MRS solid culture medium (MRS culture medium + 0.05% cysteine hydrochloride) in a streak manner, carrying out anaerobic static culture at 37 ℃ for 48h, carrying out subculture for 2-3 times by using the MRS culture medium, mixing 1mL of the culture medium of the lactobacillus reuteri CCFM1178 with 9.0mL of artificial simulated gastric juice (MRS culture medium containing 1% pepsin and pH 2.5), carrying out anaerobic culture at 37 ℃, sampling at 0h, 0.5h, 1h and 2h respectively, carrying out pouring culture by using an agar MRS culture medium, carrying out plate colony counting, and calculating the survival rate according to the viable count. The survival rate is the ratio of the number of viable bacteria at the time of sampling the culture medium to the number of viable bacteria at 0h, and is expressed as%.
Adding 1mL culture solution of Lactobacillus reuteri CCFM1178 into 9.0mL artificial simulated intestinal fluid (MRS culture medium containing 0.3% of bovine bile salt, 1% of trypsin and pH 8.0), anaerobically culturing at 37 deg.C, sampling at 0h, 0.5h, 1h and 2h, respectively, pouring and culturing with MRS agar culture medium, counting plate colony, and calculating survival rate according to viable count. The survival rate is the ratio of the number of viable bacteria at the time of sampling the culture medium to the number of viable bacteria at 0h, and is expressed as%. The results of the experiment are shown in tables 1 and 2. The result shows that the Lactobacillus reuteri CCFM1178 has better tolerance to the artificial gastrointestinal fluid.
TABLE 1 tolerance of Lactobacillus reuteri CCFM1178 in simulated gastric fluid
TABLE 2 tolerance of Lactobacillus reuteri CCFM1178 in artificially simulated intestinal fluid
Example 3: safety verification of C57BL/6J mice by Lactobacillus reuteri CCFM1178
Suspending cells of Lactobacillus reuteri CCFM1178 in physiological saline to obtain a concentration of 1 × 10 10 CFU/mL of bacterial suspension. 8 healthy male C57BL/6J mice with the weight of about 20g are taken, after the environment is adapted for one week, the bacterial suspension with the concentration is administered for intragastric administration once per day by 0.2ml, observed for one week, and the death and weight conditions are recorded.
The results are shown in Table 3. Feeding concentration of 1 × 10 10 The CFU/mL Lactobacillus reuteri CCFM1178 has no obvious influence on the mouse, the weight of the mouse has no obvious change, the appearance of the mouse has no obvious pathological symptoms, and no death phenomenon is generated.
TABLE 3 weight change and mortality in mice
Note-no death of the mice.
Example 4: lactobacillus reuteri CCFM1178 has recovery effect on intestinal dysbacteriosis caused by high-fat feed
48 healthy male C57BL/6J mice, weighing 20-21g, were acclimated for 1 week and randomized into 6 groups: blank control group (NC), high fat model control group (HFD), Simvastatin control group (Simvastatin), Metformin control group (Metformin), Lactobacillus reuteri CCFM1178 dry control group (CCFM1178), Lactobacillus reuteri NCIMB 30242 dry control group (NCIMB 30242), each group contains 8 mice; wherein, the lactobacillus reuteri NCIMB 30242 is a commonly used commercial health product strain, the simvastatin is a commonly used medicament for reducing blood fat, and the metformin is a commonly used medicament for controlling type 2 diabetes.
Respectively culturing Lactobacillus reuteri CCFM1178 and NCIMB 30242, mixing the bacterial sludge with protective agent (100g/L-150g/L skimmed milk powder, 100g/L-150g/L maltodextrin, 140g/L-160g/L trehalose) at a ratio of 1:2(w/v, 1g bacterial sludge: 2mL protective agent solution), pre-freezing at-15-20 deg.C for 8-14h, vacuum freeze-drying to obtain lyophilized bacterial powder, and suspending the lyophilized bacterial powder in physiological saline to make the concentration of Lactobacillus reuteri in physiological saline suspension be 1 × 10 10 CFU/mL, used for gavage of mice, and the grouping and treatment method of experimental animals are shown in Table 4.
TABLE 4 groups of experimental animals
The body weight of the mice was monitored periodically during the experiment.
At the end of the test, fresh mouse feces are collected and frozen at-80 ℃, genome DNA in the feces is extracted for 16s rDNA sequencing, and the structure of intestinal flora is analyzed by a second-generation sequencer. At the end of the test, the mice are fasted and are not forbidden to be watered for 12 hours, after the mice are anesthetized by injecting a 10% chloral hydrate solution into the abdominal cavity, the heart is sampled and killed by means of cervical dislocation. Centrifuging blood sample at 4 deg.C for 15min at 3000 Xg, collecting supernatant, and freezing at-80 deg.C for measuring related serum index. Collecting part of liver, rapidly placing in pre-cooled normal saline for rinsing and removing blood, placing in paraformaldehyde for fixation, freezing the rest part of liver in liquid nitrogen at a medium speed, transferring to-80 ℃ for freezing storage, and subsequently preparing into liver homogenate for measuring related indexes, wherein the specific preparation method comprises the following steps: weighing a certain amount of liver tissue, and carrying out the following steps: adding physiological saline at a ratio of 9, grinding tissue, centrifuging at 3000r for 10min, and freezing the supernatant at-80 deg.C.
The results of the flora analysis experiments are shown in FIG. 1. Compared with the HFD group, the intervention of lactobacillus reuteri CCFM1178 (CCFM1178 group) can alleviate the abnormal abundance of intestinal microorganisms of bacillus, acetti factor, ruminococcus, Eubacterium _ coprostanogens _ group, Clostridium _ sense _ stricoto _1, and rombouuthsia in mouse intestinal flora caused by high fat diet.
Example 5: lactobacillus reuteri CCFM1178 reduces the weight gain percentage, epididymal fat index and brown fat index of mice with metabolic syndrome
The grouping, modeling and treatment methods of the C57BL/6J mice are the same as example 4. The weight gain percentage, epididymal fat index and brown fat index were calculated by weighing.
The results of the experiment are shown in FIG. 2. The body weight of the mice in the model group is obviously increased, and the lactobacillus gasseri CCFM1178 obviously reduces the weight gain percentage and the white fat index (white fat/body weight) of the mice, reduces 19.38 percent and 36.7 percent relative to the model group, increases the brown fat index (brown fat/body weight), is 1.65 times of that of the model group, and is also superior to the strain CCFM1145 (brown fat index 0.0045) disclosed in CN 112322527A. Its ability to reduce body weight levels in mice was significantly higher than both drug groups and lactobacillus reuteri NCIMB 30242.
Example 6: lactobacillus reuteri CCFM1178 for reducing daily dietary intake and energy efficiency of mice with metabolic syndrome
The grouping, modeling and treatment methods of the C57BL/6J mice are the same as example 4. The dietary intake and energy efficiency were calculated by weighing.
The results of the experiment are shown in FIG. 3. The daily dietary intake and energy efficiency of the mice in the model group are obviously improved, and the daily dietary intake and energy efficiency of the mice are obviously reduced by the lactobacillus reuteri CCFM 1178. The ability to reduce the daily dietary intake level of mice was slightly higher than that of simvastatin, metformin and lactobacillus reuteri NCIMB 30242, which are drugs, and were reduced by 4.93%, 5.01% and 3.87% respectively.
Example 7: lactobacillus reuteri CCFM1178 reduces serum Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in mice with metabolic syndrome
Grouping, modeling and treatment methods of C57BL/6J mice are the same as example 4, and at the end of the test, the mice are fasted for 12 hours without water prohibition, and blood is collected from the heart after the anesthesia of 10% chloral hydrate solution injected into the abdominal cavity. The blood sample was centrifuged at 3000 Xg at 4 ℃ for 15min, the supernatant was collected, and the Total Cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) contents in the blood were measured by the detection method of the kit.
The results of the experiment are shown in FIG. 4. As can be seen from FIG. 4, the serum total cholesterol level of the mice in the high-fat diet group is obviously increased to 5.05mmol/L, the Lactobacillus reuteri CCFM1178 for intragastric administration can reduce the serum total protein cholesterol and low-density lipoprotein cholesterol levels to 3.68mmol/L and 0.71mmol/L, the recovery capability of the Lactobacillus reuteri CCFM1178 on the serum total cholesterol level is obviously stronger than that of a control medicament and the Lactobacillus reuteri NCIMB 30242, and is also better than that of the strain CCFM1145 disclosed in CN112322527A (TC 3.78mmol/L, LDL-C0.72 mmol/L), and the Lactobacillus reuteri CCFM1178 has a positive effect on blood lipid metabolism is suggested.
Example 8: lactobacillus reuteri CCFM1178 reduces the level of proinflammatory factors IL-6 and TNF-alpha in liver of mice with metabolic syndrome
The grouping, modeling and treatment method of the C57BL/6J mice are the same as example 4, and at the end of the test, the mice are fasted for 12 hours without water prohibition, and after the mice are anesthetized by injecting a 10% chloral hydrate solution into the abdominal cavity, the heart is sampled, and the cervical vertebra is dislocated and killed. Freezing and storing liver at-80 deg.C, weighing a certain amount of liver tissue during measurement, and performing the following steps: adding physiological saline in a proportion of 9 for tissue grinding, centrifuging at 3000r for 10min, taking supernatant, and determining the content of proinflammatory factors IL-6 and TNF-alpha in the liver according to a detection method of the kit. Since the drug ameliorated metabolic syndrome by a different route from microorganisms, the drug group was not tested in this example.
The results of the experiment are shown in FIG. 5. The experimental result shows that compared with a normal control group, the contents of proinflammatory factors IL-6 and TNF-alpha in the liver of a mouse in a high-fat diet group are obviously increased, the Lactobacillus reuteri CCFM1178 in gavage can reduce the contents of the proinflammatory factors IL-6 and TNF-alpha in the liver to 1173.36pg/mg protein and 4862.37pg/mg protein, and the levels are recovered to be equivalent to that of a blank group, and the intervention capability of the Lactobacillus reuteri CCFM1178 on the proinflammatory factors in the liver is obviously stronger than that of the control group and the Lactobacillus reuteri NCIMB 30242.
Example 9: lactobacillus reuteri CCFM1178 reduces the level of anti-inflammatory factor IL-10 in the liver of mice with metabolic syndrome
The grouping, modeling and treatment method of the C57BL/6J mice are the same as example 4, and at the end of the test, the mice are fasted for 12 hours without water prohibition, and after the mice are anesthetized by injecting a 10% chloral hydrate solution into the abdominal cavity, the heart is sampled, and the cervical vertebra is dislocated and killed. Freezing and storing liver at-80 deg.C, weighing a certain amount of liver tissue during measurement, and performing the following steps: adding physiological saline at a ratio of 9 for tissue grinding, centrifuging at 3000r for 10min, collecting supernatant, and determining the content of anti-inflammatory factor IL-10 in liver according to the detection method of the kit. Since the drug ameliorated metabolic syndrome by a different route from microorganisms, the drug group was not tested in this example.
The results of the experiment are shown in FIG. 6. As can be seen from the experimental results, compared with a normal control group, the content of the liver anti-inflammatory factor IL-10 of mice in a high-fat diet group is remarkably increased to 1169.76pg/mg protein, the content of the liver anti-inflammatory factor IL-10 of the lactobacillus reuteri CCFM1178 in the gavage can be increased to 1169.72U/mg protein, and the level of the lactobacillus reuteri CCFM1178 in preventing the metabolic syndrome is remarkably higher than that of a control medicament and lactobacillus reuteri NCIMB 30242.
Example 10 Lactobacillus reuteri CCFM1178 reduction of serum Lipopolysaccharide (LPS) endotoxin levels in mice with Metabolic syndrome
Grouping, modeling and treatment methods of C57BL/6J mice are the same as example 4, and at the end of the test, the mice are fasted for 12 hours without water prohibition, and blood is collected from the heart after the mice are anesthetized by intraperitoneal injection of 10% chloral hydrate solution. Centrifuging blood sample at 3000 Xg and 4 deg.C for 15min, collecting supernatant, and determining Lipopolysaccharide (LPS) endotoxin content in blood according to the detection method of the kit.
The results of the experiment are shown in FIG. 7. As can be seen from FIG. 7, the serum LPS content of the mice in the high-fat diet group is obviously increased to 348.7EU/L, the lactobacillus reuteri CCFM1178 for intragastric administration can reduce the serum LPS content to 123.2EU/L, and the recovery capability of the lactobacillus reuteri CCFM1178 for the serum LPS content is obviously stronger than that of a control medicament and lactobacillus reuteri NCIMB 30242, which indicates that the lactobacillus reuteri CCFM1178 has a positive effect on the induction of inflammation by bacterial Lipopolysaccharide (LPS) endotoxin.
Example 11 Lactobacillus reuteri CCFM1178 increase the expression level of claudin in colonic tissue of mice with metabolic syndrome
Grouping, modeling and treating methods of C57BL/6J mice are the same as example 4, and at the end of the test, the mice are fasted for 12 hours without water prohibition, are anesthetized by intraperitoneal injection of 10% chloral hydrate solution, are subjected to heart blood collection, and are killed by dislocation of cervical vertebrae. Freezing and storing mouse colon at-80 ℃, weighing a certain amount of colon tissue during measurement, and mixing the colon tissue with the frozen colon tissue according to the proportion of 1: adding physiological saline at a ratio of 9 for tissue grinding, centrifuging at 3000r for 10min, taking supernatant, and determining expression levels of zon-1, Occludin and Claudin-1 genes in colon tissue according to the detection method of the kit.
The results of the experiment are shown in FIG. 8. The expression levels of ZO-1, Occludin and Claudin-1 genes of the lactobacillus reuteri CCFM1178 stem group are obviously higher than those of the model group, and the expression levels of the ZO-1, Occludin and Claudin-1 genes are respectively raised back to 0.912, 0.976 and 1.121, which are close to the blank group; and the expression levels of ZO-1, Occludin and Claudin-1 genes of the lactobacillus reuteri NCIMB 30242 stem group have no significant difference with the expression levels of the model group, which shows that the lactobacillus reuteri CCFM1178 has better effect on maintaining the colon barrier structure.
Example 12: preparation of fermentation agent containing Lactobacillus reuteri CCFM1178
MRS culture medium: 10g of tryptone, 10g of beef extract, 5g of yeast powder, 20g of glucose, 5g of sodium acetate, 2g of diammonium hydrogen citrate, 2g of dipotassium hydrogen phosphate, 0.5g of magnesium sulfate heptahydrate, 801ml of tween and 0.25g of manganese sulfate monohydrate, wherein the volume of water is fixed to 1000ml, the pH value is adjusted to 6.5, and the sterilization is carried out for 15-25min at the temperature of 119-.
A protective agent: 100g/L-150g/L skimmed milk powder, 100g/L-150g/L maltodextrin and 140g/L-160g/L trehalose.
Inoculating Lactobacillus reuteri CCFM1178 into MRS culture medium, culturing at 37 deg.C under anaerobic condition for 18-20 hr, collecting thallus, and resuspending thallus cells with protective agent to make the concentration of thallus reach 10 10 CFU/ml, then suspendedCulturing the solution at 37 deg.C under anaerobic condition for 50-70min, and drying.
Optionally, the drying is vacuum freeze drying after pre-freezing for 8-14h at-15 to-20 ℃.
Example 13: application of lactobacillus reuteri CCFM1178
(1) Lactobacillus milk beverage prepared from Lactobacillus reuteri CCFM1178
The raw material skim milk is sterilized by heat at 95 ℃ for 20min, then cooled to 4 ℃, and then added with the lactobacillus reuteri CCFM1178 screened in example 1 or the leaven prepared in example 12 to ensure that the thallus concentration reaches 10 6 And (4) preserving at the temperature of more than 4 ℃ by refrigeration to obtain the milk beverage containing the viable bacteria of the lactobacillus reuteri CCFM 1178.
(2) Soybean milk prepared from Lactobacillus reuteri CCFM1178
Soaking soybeans in soft water, wherein the volume of the water is three times that of the original soybeans, soaking the soybeans for 1-2 hours at the temperature of 80 ℃, and then removing soybean hulls. And then, draining the soaking water, adding boiling water for grinding into slurry, and keeping the temperature for 10-15 min under the condition that the temperature is higher than 80 ℃. Filtering the slurry with a 150-mesh filter membrane, centrifuging to obtain a centrifugal liquid, namely coarse soybean milk, heating the centrifugal liquid to the temperature of 140-150 ℃, rapidly introducing the hot coarse soybean milk into a vacuum cooling chamber, and vacuumizing, wherein peculiar smell substances in the coarse soybean milk are rapidly discharged along with water vapor. After vacuum degassing, the temperature is reduced to about 37 ℃, and then the lactobacillus reuteri CCFM1178 screened in the embodiment 1 or the leaven prepared in the embodiment 12 is inoculated to ensure that the concentration of the lactobacillus reuteri CCFM1178 reaches 10 6 And (3) preserving the soybean milk at the temperature of more than 4 ℃ by refrigeration to obtain the soybean milk containing the viable bacteria of the lactobacillus reuteri CCFM 1178.
(3) Fruit and vegetable beverage prepared from lactobacillus reuteri CCFM1178
Selecting fresh vegetables (such as one or more of cucumber, carrot, beet, celery or cabbage), cleaning, juicing, instantly sterilizing at 140 deg.C for 2s, immediately cooling to about 37 deg.C, inoculating the Lactobacillus reuteri CCFM1178 starter to make its concentration reach 10 6 More than CFU/mL, and refrigerating at 4 deg.C to obtain CCFM117 containing Lactobacillus reuteri8 live bacteria fruit and vegetable beverage.
(4) Capsule product prepared from lactobacillus reuteri CCFM1178
The lactobacillus reuteri CCFM1178 is cultured on an MRS culture medium for 24 hours, centrifuged for 20 minutes at the temperature of 4 ℃ and at the speed of 4000r/min, washed twice by PBS, added with skim milk powder accounting for 4 percent of the weight of the finally obtained powder containing the lactobacillus reuteri CCFM1178 and lactose accounting for 6 percent of the weight of the finally obtained powder, mixed for 10 minutes, added with sterile 2 percent calcium chloride and 3 percent sodium alginate, stirred for 10 minutes at the speed of 150r/min, then statically solidified for 30 minutes, finally cleaned and filtered, and the obtained filtrate is frozen and dried for 20 hours to obtain powder containing the lactobacillus reuteri CCFM1178, and the powder is filled into commercial medicinal microcapsules to obtain the capsule product.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (9)
1. L. reuteri bacterium (A), (B)Lactobacillus reuteri) CCFM1178, which was deposited at the Guangdong province culture Collection on 19 th 3/2021 with GDMCC number 61574.
2. Use of lactobacillus reuteri CCFM1178 according to claim 1 for the preparation of a medicament.
3. The use according to claim 2, wherein the medicament has at least one of the following functions:
(a) relief of metabolic syndrome;
(b) regulating intestinal flora;
(c) relieving irritable bowel syndrome;
(d) relieving inflammation and/or fibrosis of liver tissue.
4. A microbial preparation comprising the lactobacillus reuteri CCFM1178 of claim 1, wherein said microbial preparation comprises wet cells or lyophilized cells of the lactobacillus reuteri CCFM1178 of claim 1.
5. A functional food or health food comprising the Lactobacillus reuteri CCFM1178 of claim 1.
6. Fermented food product comprising the lactobacillus reuteri CCFM1178 of claim 1, wherein the fermented food product is produced by fermentation using lactobacillus reuteri CCFM1178, and comprises solid, liquid or semi-solid food products.
7. A medicament containing Lactobacillus reuteri CCFM1178 of claim 1, wherein the content of said Lactobacillus reuteri CCFM1178 in the medicament is more than or equal to 1 x 10 8 CFU/g or 1X 10 8 CFU/mL。
8. The medicament of claim 7, further comprising a pharmaceutically acceptable excipient.
9. Use of lactobacillus reuteri CCFM1178 according to claim 1 for the preparation of a fermented food product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110773458.0A CN113403231B (en) | 2021-07-08 | 2021-07-08 | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110773458.0A CN113403231B (en) | 2021-07-08 | 2021-07-08 | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113403231A CN113403231A (en) | 2021-09-17 |
| CN113403231B true CN113403231B (en) | 2022-09-06 |
Family
ID=77685696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110773458.0A Active CN113403231B (en) | 2021-07-08 | 2021-07-08 | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113403231B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114107088B (en) * | 2021-10-20 | 2023-07-21 | 山西大学 | Lactobacillus reuteri LRSY523 and application thereof |
| CN114010665A (en) * | 2021-11-30 | 2022-02-08 | 西南医科大学附属医院 | Application of lactobacillus reuteri in preparation of medicine for preventing and/or treating alcoholic liver disease |
| CN114344344B (en) * | 2022-01-05 | 2023-06-13 | 东北农业大学 | Application of lactobacillus reuteri in relieving obesity function of high-fat diet-induced mice and compound containing lactobacillus reuteri |
| CN114410533A (en) * | 2022-01-27 | 2022-04-29 | 江南大学 | Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis |
| CN116509906B (en) * | 2023-03-23 | 2024-04-02 | 浙江大学 | Application of lactobacillus reuteri ZJ617 in improving non-alcoholic fatty liver disease and fat accumulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI627959B (en) * | 2014-10-02 | 2018-07-01 | 景岳生物科技股份有限公司 | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual |
| CN105853467B (en) * | 2015-01-20 | 2019-07-26 | 景岳生物科技股份有限公司 | Lactobacillus reuteri GMNL-263 is used to prepare the purposes of blood-fat reducing composition |
| CN110468070A (en) * | 2019-08-19 | 2019-11-19 | 江南大学 | Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process |
| CN111004757B (en) * | 2019-12-31 | 2021-11-02 | 深圳市沁帆科技有限公司 | Lactobacillus reuteri, microbial agent and food product |
| CN111658676B (en) * | 2020-06-11 | 2021-12-31 | 湖州金诺康健康科技有限公司 | Application of viable lactobacillus reuteri in preparation of medicine for treating or relieving symptoms of non-alcoholic fatty liver disease |
| CN112322527A (en) * | 2020-11-03 | 2021-02-05 | 江南大学 | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof |
| CN112646744B (en) * | 2020-12-28 | 2023-03-24 | 江南大学 | Application of lactobacillus reuteri in preventing and relieving ulcerative colitis |
-
2021
- 2021-07-08 CN CN202110773458.0A patent/CN113403231B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113403231A (en) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112322528B (en) | Lactobacillus rhamnosus capable of intervening metabolic syndrome and application thereof | |
| CN113403231B (en) | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof | |
| CN112322527A (en) | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof | |
| CN107523526B (en) | Lactobacillus reuteri and application thereof | |
| KR102146429B1 (en) | Strain of bifidobacterium animalis ssp. animalis | |
| CN112342175B (en) | Vaginal health probiotic composition and application thereof | |
| WO2022206300A1 (en) | Composition capable of facilitating defecation and use thereof | |
| KR20190068078A (en) | Lactobacillus paracasei AO356 strain with Anti-Obesity Ability and Composition for treatment or improvement or preventing of obesity comprising the same | |
| CN113943681B (en) | Bifidobacterium longum capable of reducing inflammatory reaction and relieving constipation | |
| KR102279283B1 (en) | Composition for preventing, alleviating, or treating NAFLD comprising Lactobacillus helveticus and Bifidobacterium species | |
| CN111996153A (en) | Bifidobacterium breve and application thereof | |
| CN111560325B (en) | Lactobacillus fermentum capable of regulating intestinal tight junction protein and application thereof | |
| CN113122472A (en) | Bacteroides vulgatus capable of protecting intestinal permeability and application thereof | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN110106104B (en) | Bifidobacterium pseudocatenulatum CCFM1048, composition thereof, fermented food, application, microbial inoculum and preparation method of microbial inoculum | |
| CN116024129A (en) | Lactobacillus crispatus capable of co-aggregating with helicobacter pylori and application thereof | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN111869879B (en) | Product capable of regulating CYP1A1 gene expression | |
| CN114410532A (en) | Bifidobacterium longum for reducing plasma trimethylamine oxide and caecum trimethylamine levels and application thereof | |
| CN114381406A (en) | Bifidobacterium breve CCFM1217 capable of simultaneously reducing blood plasma and caecum trimethylamine and application thereof | |
| CN113005066A (en) | Compound bifidobacterium preparation with antiallergic, immunity enhancing, blood sugar reducing, blood fat reducing and weight losing functions and preparation method thereof | |
| CN114561325B (en) | Bifidobacterium longum capable of changing bile acid content in simulated gastrointestinal tract environment and having constipation relieving effect and application thereof | |
| CN115721017B (en) | Bifidobacterium breve capable of activating anti-inflammatory target spot of intestinal tract and application | |
| CN115029271B (en) | Lactobacillus salivarius capable of down regulating serum glutamyl transpeptidase activity after drinking and application thereof | |
| CN113699061B (en) | Bacterial strain Phocae eicola sp capable of relieving ulcerative colitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |